Anti-Dxd (Exatecan derivative for ADC) antibody, mAb
Background
Dxd (Exatecan derivative for ADC) is a potent DNA topoisomerase I inhibitor, with an IC50 of 0.31 μM, used as a
conjugated drug of HER2-targeting ADC (DS-8201a). Dxd is cytotoxic to human cancer cell lines of KPL-4,
NCI-N87, SK-BR-3, and MDA-MB-468 with IC50s of 1.43 nM-4.07 nM, but the control IgG-ADC (Dxd is the
payload) shows no inhibition on the four cell lines (with HER2 expression).
#YKMP18020 monoclonal antibody can recognize Dxd and Dxd structurally similar molecules.
Immunogen: Dxd-KLH
Specificity: Specifically recognizes the target-DXD
Source: Mouse, Monoclonal Clone #13
Isotype: IgG1
Conjugate: Unconjugated
Concentration: 1.0 mg/ml
Purity: > 90% as determined by SDS-PAGE
Tested applications: ELISA
Recommended dilution: 1:1,000-1:5,000 (optimal dilutions should be determined by the end use.)
Storage Buffer: PBS Buffer, pH7.4
Storage: Store at 2°C to 8°C for 1 week. For long term storage, aliquot and store at -20°C to -80°C. Stable for 2
years from date of receipt. Aliquot to avoid repeated freezing and thawing
* Please note: FOR RESEARCH USE ONLY
